

Injectable Targeted Therapy Market 2025-2029: Unveiling Growth Developments with the Latest Updates

*The Business Research Company's
Injectable Targeted Therapy Global
Market Report 2025 – Market Size,
Trends, And Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, October 13, 2025

/EINPresswire.com/ -- What Is The
Expected Cagr For The [Injectable
Targeted Therapy Market](#) Through 2025?

The market size of injectable targeted therapy has seen a swift expansion in the past few years. An increase from \$57.97 billion in 2024 to \$64.22 billion in 2025, at a compound annual growth rate (CAGR) of 10.8%, is predicted. The significant growth experienced during the historic period



Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors”

*The Business Research
Company*

can be credited to a rise in clinical trials centered on injectable targeted therapies, heightened emphasis on precision oncology and immunotherapy, increased reception of supportive reimbursement policies concerning biologic therapies, patient inclination towards minimally invasive treatment alternatives, and a surge in regulatory approvals concerning new injectable targeted therapies.

The market size for injectable targeted therapy is projected to witness swift expansion in the upcoming years, reaching

\$95.46 billion by 2029, with a CAGR of 10.4%. This anticipated growth over the forecast period can be attributed to factors such as the growing prevalence of both chronic and rare diseases, an increase in the demand for personalized medicine, greater acceptance of biologics over traditional treatments, enhanced awareness of targeted therapies among healthcare practitioners, and increased investment in biotechnology and pharmaceutical R&D. Key trends to watch for within the forecast period include technology-led breakthroughs in monoclonal antibodies, the incorporation of digital health platforms for patient surveillance, advancements in antibody-drug conjugates and bispecific antibodies for cancer treatment, and progression in

The Business
Research Company

The Business Research Company



personalized medicine strategies.

Download a free sample of the [injectable targeted therapy market report](https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp):
<https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp>

What Are The Driving Factors Impacting The Injectable Targeted Therapy Market?

The growth of the injectable targeted therapy market is predicted to accelerate due to the rising demand for personalized medicine. The term "personalized medicine" is used to describe a healthcare model that customizes prevention, diagnosis, and treatment measures based on the individual's genetic, environmental, and lifestyle elements. Developments in genomics fuel the expansion of personalized medicine, providing a more profound comprehension of individual genetic variations, thereby facilitating more accurate, targeted treatments that enhance patient outcomes and decrease the chances of error in treatment methods. Injectable targeted therapy facilitates personalized medicine by administering drugs tailored to a patient's unique molecular or genetic disease features, enhancing the effectiveness and minimizing potential side effects. For instance, the Personalized Medicine Coalition, a non-profit organization based in the US, reported in February 2024 that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from six in 2022. In addition to this, the FDA also gave the green light to seven cancer drugs and three treatments for a variety of other diseases and conditions in 2023. Consequently, the growing demand for personalized medicine is propelling the injectable targeted therapy market's development.

Which Players Dominate The Injectable Targeted Therapy Industry Landscape?

Major players in the Injectable Targeted Therapy Global Market Report 2025 include:

- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi SA
- Novartis AG
- AstraZeneca plc
- Bristol-Myers Squibb Company

What Are The Top Trends In The Injectable Targeted Therapy Industry?

Prominent entities in the injectable targeted therapy market are employing their efforts to conceive innovative solutions, such as the subcutaneous injection. These solutions aim to increase the efficacy of drug delivery, amplify patient adherence, and more specifically direct disease pathways. A subcutaneous injection is a delivery method involving the administration of medication beneath the skin into the subcutaneous fat layer which lets the drug seep slowly into the bloodstream. Eisai Co., Ltd., a pharmaceutical corporation from Japan, in collaboration with Biogen Inc., a U.S. biotech company, is an apt illustration of this trend. They secured FDA

approval in August 2025 for LEQEMBI IQLIK, an early Alzheimer's disease remedy. This treatment involves a handy, once-weekly subcutaneous injection for the maintenance treatment of early Alzheimer's disease. It enables patients to administer the drug themselves at home following the initial intravenous therapy. This form of treatment targets and removes amyloid beta plaques and protofibrils, the primary elements driving Alzheimer's progression. The treatment is time-efficient, reduces the incidence of systemic side effects compared to IV infusions, and decreases the requirement for visits to the infusion centre. These constitute greater independence for both patients and their caregivers.

Global Injectable Targeted Therapy Market Segmentation By Type, Application, And Region

The injectable targeted therapy market covered in this report is segmented as

- 1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types
- 2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation
- 3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular
- 4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications
- 5) By End User: Hospitals, Specialty Clinics, Research Laboratories

Subsegments:

- 1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
- 2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors
- 3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins
- 4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics

View the full injectable targeted therapy market report:

<https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report>

Which Region Holds The Largest Market Share In The Injectable Targeted Therapy Market?

In 2024, North America held the most significant share in the global injectable targeted therapy market. It's predicted that the Asia-Pacific region will experience the most rapid growth for the forecasted period. The report covers territories including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Injectable Targeted Therapy Market 2025, By [The Business Research Company](#)

Type 2 Diabetes Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report>

Non Insulin Therapies For Diabetes Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report>

Diabetic Gastroparesis Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/diabetic-gastroparesis-treatment-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/856993312>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.